Skip to main content
Equibles
PYXS logo

PYXS · Pyxis Oncology, Inc. · Metrics

Track PYXS — free

Use PYXS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PYXS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.68 -0.03 (-1.75%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$140.13M
Shares
83.41M
Volume · Oct 23 626.79K Avg daily vol (3M) 1.23M

PYXS metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.68
Market cap
$140.13M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
-41.3%
Price change (3M)
-35.6%
Price change (6M)
-11.6%
Price change (YTD)
+46.1%
Price change (1Y)
-50.3%
Trailing year
Price change (5Y)
-87.1%
52-week high
$5.34
52-week low
$1.06
Change from 52-week high
-68.5%
Change from 52-week low
+58.5%
Annualized volatility
125.4%
Annualized volatility (3M)
115.7%
Beta
1.3
RSI (14D)
28.8
Price vs SMA 50
-39.6%
Price vs SMA 200
-22.1%
Avg volume (3M)
1.23M
Relative volume
0.5
Average dollar volume
$3.46M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
83.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
12.2
reciprocal yield 8.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-63.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-20

Profitability

9 metrics
Gross margin
82.8%
Operating margin
-609.2%
Trailing 12 months
Net margin
-574.5%
Gross profit (TTM)
$15.67M
Operating profit (TTM)
−$92.11M
Net income (TTM)
−$88.73M
Trailing 12 months
Diluted EPS (TTM)
$-1.40
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$0.31
Operating profit per diluted share (TTM)
$-1.46
EBITDA per diluted share (TTM)
$-1.39
Net income per diluted share (TTM)
$-1.40
Operating cash flow per diluted share (TTM)
$-1.07
Free cash flow per diluted share (TTM)
$-1.01
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$1.19
Stock compensation per diluted share (TTM)
$0.19
Book value per share
$0.85

Growth

11 metrics
Revenue growth YoY
-14.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-775.6%
Return on assets
-161.6%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
−$87.92M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$33.00M
Latest balance sheet
Cash & equivalents
$18.86M
Total assets
$54.92M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$67.91M
Capital expenditures (TTM)
$237,000
R&D (TTM)
$75.56M
SG&A (TTM)
—
Stock compensation (TTM)
$11.89M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
79
13F filer change QoQ
+1
Institutional ownership
41.6%
Conviction holders (share of 13F filers)
2.6%
Crowding (high-turnover and private-fund holders)
16.4%
Private-fund adviser ownership
15.1%
Active holders' share change QoQ
+27.9%
Holder tenure
7.6
Price vs estimated holder cost
-14.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.7%

Short interest

3 metrics
Short interest
5.9%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1782223 CUSIP 747324101 13F (30d) 9 filings 9 filers Visit website Investor relations